CD86 antagonist multi-target binding proteins

US9493564B2 · kind B2 · utility

Assignee

• Aptevo Research and Development LLC · US

Inventors

• Peter Armstrong Thompson · Bellevue, US
• Peter Robert Baum · Seattle, US
• Philip Tan · Seattle, US
• John W. Blankenship · Acton, US
• Sateesh Natarajan · Redmond, US

Key dates

• Filing date: Oct 2, 2009
• Grant date: Nov 15, 2016
• Expiry date: Jul 30, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.